

# Nationally, 80% of commercially insured patients have access to QBREXZA™ (glycopyrronium) cloth for as little as \$35 with the QBREXZA Copay Card<sup>1,\*</sup>



Most commercial insurance plans require a Prior Authorization (PA) or Medical Exception (ME)

QBREXZA is the first and only FDA-approved, once-daily anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.

Completing a PA or ME will allow most patients to get QBREXZA for as little as \$35 per fill with the copay card. Some patients may pay less depending on their insurance.\*

Health plans commonly require the following criteria to be met prior to providing coverage for QBREXZA to ensure use in the appropriate patient population:

- Patient is 9 years of age or older
- Diagnosis of primary axillary hyperhidrosis: ICD-10 Code L74.510
- Trial of prescription-strength antiperspirant (e.g., Drysol) or clinical-strength over-the-counter (OTC) antiperspirant and rationale for failure/discontinuation
- Physician attestation to significant impairment of the patient's participation in daily activities

Log in to [CoverMyMeds.com](https://CoverMyMeds.com) to initiate an electronic PA or ME request, for quick coverage determination.

Please see the QBREXZA copay card program updates on the reverse side

## IMPORTANT SAFETY INFORMATION

**Contraindications:** QBREXZA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of QBREXZA (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren's syndrome).

### WARNINGS AND PRECAUTIONS

**Worsening of Urinary Retention:** QBREXZA should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hypertrophy or bladder-neck obstruction. Instruct patients to discontinue use immediately and consult a physician should any of these signs or symptoms develop. Patients with a history of urinary retention were not included in the clinical studies.

**Control of Body Temperature:** In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

**Operating Machinery or an Automobile:** Transient blurred vision may occur with use of QBREXZA. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery, or performing hazardous work until the symptoms have resolved.

\*Depending on eligibility and status of coverage. See full terms and conditions at [www.QBREXZA.com/savings-and-support](https://www.QBREXZA.com/savings-and-support).

## QBREXZA™ (glycopyrronium) cloth Copay Card Program Is Changing, Effective April 1, 2019

Please complete a PA/ME to ensure that patients are getting the lowest out-of-pocket cost for QBREXZA.

<b>\$35 copay card will still be available with a \$200 maximum cap per fill</b>	<b>\$70 copay card will no longer be available</b>
<ul style="list-style-type: none"><li>Eligible commercially insured patients can still pay as little as \$35 per fill. Some patients may pay less depending on their insurance</li></ul>	<ul style="list-style-type: none"><li>Eligible patients currently using the \$70 copay card will be able to receive one additional fill between April 1 and June 30, 2019, if they have not exceeded the program maximum cap of \$2500</li><li>Commercially insured patients on the \$70 copay card may be eligible for the \$35 copay card</li></ul>
<b>The program maximum cap is \$2500 through December 31, 2019</b>	



Patients can download the copay card from [www.QBREXZA.com/savings-and-support](http://www.QBREXZA.com/savings-and-support).

For additional questions, visit [www.QBREXZA.com/HCP](http://www.QBREXZA.com/HCP), chat online with a DermiraConnect support specialist at [www.DermiraConnect.com/HCP](http://www.DermiraConnect.com/HCP) or call us at 1-877-DERMIRA (1-877-337-6472) (Monday-Friday, 8 am-8 pm EST).

## IMPORTANT SAFETY INFORMATION (continued)

### ADVERSE REACTIONS

The most common adverse reactions seen in  $\geq 2\%$  of subjects treated with QBREXZA were dry mouth (24.2%), mydriasis (6.8%), oropharyngeal pain (5.7%), headache (5.0%), urinary hesitation (3.5%), vision blurred (3.5%), nasal dryness (2.6%), dry throat (2.6%), dry eye (2.4%), dry skin (2.2%) and constipation (2.0%). Local skin reactions, including erythema (17.0%), burning/stinging (14.1%) and pruritus (8.1%) were also common.

### DRUG INTERACTIONS

**Anticholinergics:** Coadministration of QBREXZA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of QBREXZA with other anticholinergic-containing drugs.

### INSTRUCTIONS FOR ADMINISTERING QBREXZA

Instruct patients to use one cloth to apply QBREXZA to both axillae by wiping the cloth across one underarm, ONE TIME. Using the same cloth, apply the medication to the other underarm, ONE TIME. Inform patients that QBREXZA can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes.

Instruct patients to wash their hands with soap and water immediately after discarding the used cloth.

### USE IN SPECIFIC POPULATIONS

**Pregnancy:** There are no available data on QBREXZA use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.

**Lactation:** There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for QBREXZA and any potential adverse effects on the breastfed infant from QBREXZA or from the underlying maternal condition.

**Renal Impairment:** The elimination of glycopyrronium is severely impaired in patients with renal failure.

### INDICATION

QBREXZA is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.

Please [click here](#) for Full Prescribing Information and visit [QBREXZA.com](http://QBREXZA.com) for more information.

**Qbrexza™**  
(glycopyrronium) cloth